share_log

Rodman & Renshaw Initiates Coverage On Milestone Pharmaceuticals With Buy Rating, Announces Price Target of $9

Benzinga ·  Aug 22 20:04  · Ratings

Rodman & Renshaw analyst Brandon Folkes initiates coverage on Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy rating and announces Price Target of $9.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment